⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052865 | 0.68 | ALDH1A1 (0.50) | — | |
| Iodide SCHEMBL9427887 | 0.66 | SIGMAR1 (0.31) | — | |
| Formamide SCHEMBL28279597 | 0.65 | — | — | |
| Methylamine SCHEMBL28038298 | 0.64 | CYP1A2 (0.41) | — | |
| SCHEMBL2698963 | 0.64 | — | — | |
| SCHEMBL12607355 | 0.64 | — | — | |
| SCHEMBL12607353 | 0.64 | — | — | |
| SCHEMBL18435370 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL13345 | 0.63 | — | — | |
| Hydrochloric Acid SCHEMBL1785868 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-02-23 | — | — | US | disclosed |
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-02-23 | — | — | US | disclosed |
| US-8088823-B2 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-01-03 | — | — | US | disclosed |
| US-8088823-B2 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-01-03 | — | — | US | disclosed |
| EP-1501495-B1 | USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI | NABRIVA THERAPEUTICS AG (AT) | 2010-09-08 | — | — | EP | disclosed |
| US-7790749-B2 | Use of pleuromutilins for the treatment of disorders caused by Helicobacter pylori | NABRIVA THERAPEUTICS AG (AT) | 2010-09-07 | — | — | US | disclosed |
| US-7790749-B2 | Use of pleuromutilins for the treatment of disorders caused by Helicobacter pylori | NABRIVA THERAPEUTICS AG (AT) | 2010-09-07 | — | — | US | disclosed |
| EP-1875903-B1 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | NABRIVA THERAPEUTICS AG (AT) | 2010-07-28 | — | — | EP | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |